Department of Medical Specialties, Pulmonology Unit, Arcispedale Santa Maria Nuova - IRCCS, Azienda USL di Reggio Emilia, Reggio Emilia, Italy.
Pulmunology Unit and Laboratory of Citoimmunopatology, Istituti Clinici Scientifici Maugeri SpA, SB, IRCCS, Veruno (NO), Italy.
BMC Pulm Med. 2018 Feb 8;18(1):29. doi: 10.1186/s12890-017-0554-8.
Bronchial thermoplasty (BT) is a non-pharmacological intervention for severe asthma whose mechanism of action is not completely explained by a reduction of airway smooth muscle (ASM). In this study we analyzed the effect of BT on nerve fibers and inflammatory components in the bronchial mucosa at 1 year.
Endobronchial biopsies were obtained from 12 subjects (mean age 47 ± 11.3 years, 50% male) with severe asthma. Biopsies were performed at baseline (T0) and after 1 (T1), 2 (T2) and 12 (T12) months post-BT, and studied with immunocytochemistry and microscopy methods. Clinical data including Asthma Quality of Life Questionnaire (AQLQ) and Asthma Control Questionnaire (ACQ) scores, exacerbations, hospitalizations, oral corticosteroids use were also collected at the same time points.
A statistically significant reduction at T1, T2 and T12 of nerve fibers was observed in the submucosa and in ASM compared to T0. Among inflammatory cells, only CD68 showed significant changes at all time points. Improvement of all clinical outcomes was documented and persisted at the end of follow up.
A reduction of nerve fibers in epithelium and in ASM occurs earlier and persists at one year after BT. We propose that nerve ablation may contribute to mediate the beneficial effects of BT in severe asthma.
Registered on April 2, 2013 at ClinicalTrials.gov Identifier: NCT01839591 .
支气管热成形术(BT)是一种非药物干预重度哮喘的方法,其作用机制不能完全用气道平滑肌(ASM)的减少来解释。在这项研究中,我们分析了 BT 在支气管黏膜中神经纤维和炎症成分的 1 年影响。
对 12 名(平均年龄 47±11.3 岁,50%为男性)重度哮喘患者进行支气管内活检。在基线(T0)和 BT 后 1(T1)、2(T2)和 12(T12)个月时进行活检,并采用免疫细胞化学和显微镜方法进行研究。同时收集临床数据,包括哮喘生活质量问卷(AQLQ)和哮喘控制问卷(ACQ)评分、加重、住院、口服皮质类固醇使用情况。
与 T0 相比,在 T1、T2 和 T12 时,黏膜下和 ASM 中的神经纤维均有统计学意义的减少。在炎症细胞中,只有 CD68 在所有时间点均有显著变化。所有临床结果均得到改善,并在随访结束时持续存在。
上皮和 ASM 中的神经纤维减少发生较早,并在 BT 后 1 年持续存在。我们提出神经消融可能有助于介导 BT 在重度哮喘中的有益作用。
于 2013 年 4 月 2 日在 ClinicalTrials.gov 注册,标识符:NCT01839591。